Its incidence or prevalence is still unclear, and only one Japanese study reported an estimated annual incidence of 117 cases nationally.1 As the most prevalent cause of acquired hypophosphatemic osteomalacia, TIO is not as common as other common FGF23‐related hypophosphatemic diseases, such as X‐linked hypophosphatemia, which requires long‐term drug therapy and is curable by tumor resection. This evidence concerns the gene FGF23 and neoplasm.